Loading clinical trials...
Loading clinical trials...
An Exploratory Phase II Study to Determine the Safety, Tolerability and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Adults With Diagnostic and Statistical Manual Version 5 (DSM-5) Intermittent Explosive Disorder (IED)
Conditions
Interventions
SRX246
Placebo
Locations
7
United States
Atlanta Center for Medical Research
Atlanta, Georgia, United States
University of Chicago, Department of Psychiatry
Chicago, Illinois, United States
Psychiatric Care and Research Center
O'Fallon, Missouri, United States
SPRI Clinical Trials, LLC
Brooklyn, New York, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Lindner Center of HOPE
Mason, Ohio, United States
Start Date
May 1, 2014
Primary Completion Date
May 1, 2016
Completion Date
May 1, 2016
Last Updated
July 21, 2023
NCT06804525
NCT06665074
NCT00078754
NCT04819230
NCT00127400
Lead Sponsor
Azevan Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions